Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis - Quiz - MDSpire

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis

  • By

  • Vladimir Zah

  • Dimitrije Grbic

  • Filip Stanicic

  • June 30, 2026

  • 0 min

Share

Original Source(s)

Treatment characteristics and safety profiles of Belbuca®, buprenorphine patch, and oral schedule II opioids among chronic low back pain patients without a positive history of opioid-use disorder: a retrospective US commercial claims analysis

  • by Vladimir Zah, Dimitrije Grbic, Filip Stanicic

  • June 30, 2026

Related Content

Low-Dose Caffeine May Improve Aerobic Time-Trial Performance

A meta-analysis of placebo-controlled crossover trials found reduced aerobic time-trial completion times with both low- and moderate-dose oral anhydrous caffeine, but the evidence was mostly derived from male participants, cycling studies, and trials using doses no higher than 6 mg/kg.

Strengthening the rural medical workforce: the need for a paradigm shift in protecting and growing the critical role of GP supervisors

AI Model Trails Expert Skin Lesion Readers

A foundation artificial intelligence model surpassed less experienced physicians but did not outperform expert dermatologists in multiclass skin lesion diagnosis.